阿尔茨海默病病理级联中的动态生物标志物的变化点:一项为期30年的队列研究
Yuto Uchida1, Kei Nishimaki1, Anja Soldan2
1Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
概括
阿尔茨海默病的生物标志物,如粉样β和,在临床症状出现前15-20年就会出现显著的变化. 白质变性是疾病进展的早期指标.
科学领域:
- 神经科学是一个神经科学.
- 生物标志物研究 生物标志物研究
- 老年学是一门学科.
背景情况:
- 长度研究追踪生物标志物超过30年在认知不受损的个体.
- 研究了粉样β (Aβ),酸化,神经退行和炎症的轨迹.
- 检查了349名参与者从生物标志物老年人控制在痴呆风险研究.
研究的目的:
- 确定临床痴呆症发病前的生物标志物变化点.
- 确定阿尔茨海默病病理变化的时间序列.
- 建立神经退行性疾病进展的早期标志物.
主要方法:
- 在30年的纵向数据上使用了分片回归模型.
- 分析了脑脊液生物标志物,MRI衍生的大脑体积和全球认知.
- 确定了生物标志物水平和大脑结构体积的显著变化点.
主要成果:
- 在轻度认知障碍或痴呆症发病前几年,确定了生物标志物变化点.
- 粉样β (Aβ) 变化点在-17.1年,酸化在-15.8年.
- 白质和心室变化先于海马变化,表明早期的神经退行.
结论:
- 这些发现支持了阿尔茨海默病的动态生物标志物模型.
- 白质变性是阿尔茨海默氏症病理级联中显著的早期标志物.
- 生物标志物加速在临床症状表现之前15-20年.
相关概念视频
01:26Alzheimer's Disease: Overview
669
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
669
01:22Alzheimer's Disease: Treatment
262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262